247.35MMarket Cap-2.78P/E (TTM)
5.7199High5.5700Low163.10KVolume5.6800Open5.7000Pre Close919.61KTurnover0.57%Turnover RatioLossP/E (Static)43.47MShares9.010052wk High5.40P/B162.60MFloat Cap3.050052wk Low--Dividend TTM28.58MShs Float171874.8797Historical High--Div YieldTTM2.63%Amplitude2.1900Historical Low5.6380Avg Price1Lot Size
Abeona Therapeutics Stock Forum
just
Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-Cel
Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type a Meeting With FDA to Align on Upcoming Pz-Cel Bla Resubmission
Abeona Therapeutics Q2 Income From Operations USD -17.864 Million Vs. IBES Estimate USD -14.6 Million
Abeona Therapeutics 2Q Loss/Shr 26c
Abeona Therapeutics 2Q Net $7.41M
Abeona Therapeutics Q2 Cash & Investments USD 123 Million
Abeona Therapeutics: To Get Upfront Payment Upon Beacon's Exercise of Option to License Aav204, With Extra Payments on Achievement of Milestones
NEWS
Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Abeona Therapeutics Inc. announced the pricing of an underwritten offering of common stock and pre-funded warrants, expected to generate approximately $75 million in gross proceeds. The offering includes both new and existing investors, with the funds intended for the resubmission of its BLA, commercialization of its product candidate pz-cel, and ...
🗓️ Last week’s PDUFAs:
$Pfizer (PFE.US)$ : Approved 4/26 🎉
⇨ BEQVEZ (fidanacogene elaparvovec-dzkt)
▹ Hemophilia B
▹ BLA
▹ PDUFA date: Q2 2024
$Day One Biopharmaceuticals (DAWN.US)$ : Approved 4/23 🎉
⇨ OJEMDA (tovorafenib)
▹ Pediatric low-grade glioma
▹ NDA
▹ PDUFA date: 4/30/24
$ImmunityBio (IBRX.US)$ : Approved 4/22 🎉
⇨ Anktiva + BCG
▹ Bladder cancer
▹ resubmitted BLA
▹ PDUFA date: 4/23/24
$Abeona Therapeutics (ABEO.US)$ : CRL 4/22 🙁
⚠...
No comment yet